• Group
    • Companies
    • History
    • Business model
    • Mission and vision
    • Corporate values
    • Commitment to sport
  • Research
    • Pharmaceutical Research
    • Sucrosomial Technology
    • Cetylated Fatty Acids
    • Quality and certifications
  • Brands
    • PharmaNutra
      • SiderAL
      • SiderAL Forte
      • SiderAL Folico
      • Cardio SiderAL
      • SiderAL Med
      • Cetilar Crema
      • Cetilar Patch
      • Cetilar Tape
      • ApportAL
      • UltraMag
      • Gestalys DHA
      • Novomega
      • Bonecal
      • DiKappa2
    • Junia Pharma
    • Alesco
  • Investor
    • INVESTOR RELATIONS
      • Stock performance
      • Share capital and Shareholders
      • Shares study and research
      • Broker
      • Financial statements
      • Presentations
      • Corporate events
      • Company presentation
      • Notice of meetings
      • SDIR
      • AIM admission document
      • MTA prospectus
    • PRESS
      • Press releases
      • Press review
  • Governance
    • Code of Ethics
    • 231 Model
    • Board of Directors and Committees
    • Company documents
    • Internal dealing
    • Shareholders’ meeting
    • Statutory auditors and Audit firm
    • Sharholders Agreements
  • News
    • Science
    • Corporate
    • Events
    • Social commitment
  • Careers
    • Work with us
    • Job offers
    • Job application
  • Group
    • Companies
    • History
    • Business model
    • Mission and vision
    • Corporate values
    • Commitment to sport
  • Research
    • Pharmaceutical Research
    • Sucrosomial Technology
    • Cetylated Fatty Acids
    • Quality and certifications
  • Brands
    • PharmaNutra
      • SiderAL
      • SiderAL Forte
      • SiderAL Folico
      • Cardio SiderAL
      • SiderAL Med
      • Cetilar Crema
      • Cetilar Patch
      • Cetilar Tape
      • ApportAL
      • UltraMag
      • Gestalys DHA
      • Novomega
      • Bonecal
      • DiKappa2
    • Junia Pharma
    • Alesco
  • Investor
    • INVESTOR RELATIONS
      • Stock performance
      • Share capital and Shareholders
      • Shares study and research
      • Broker
      • Financial statements
      • Presentations
      • Corporate events
      • Company presentation
      • Notice of meetings
      • SDIR
      • AIM admission document
      • MTA prospectus
    • PRESS
      • Press releases
      • Press review
  • Governance
    • Code of Ethics
    • 231 Model
    • Board of Directors and Committees
    • Company documents
    • Internal dealing
    • Shareholders’ meeting
    • Statutory auditors and Audit firm
    • Sharholders Agreements
  • News
    • Science
    • Corporate
    • Events
    • Social commitment
  • Careers
    • Work with us
    • Job offers
    • Job application
  • it
  • en

11 October 2021

STAR Conference Fall Edition 2021: PharmaNutra meets with analysts and investors

After the meeting in April for the Spring Edition, the appointment with the STAR Conference of the Borsa Italiana (Italian […]

12 May 2021

PharmaNutra joined TP ICAP Midcap Conference

Over 180 international investors and 140 companies attended the event, in which Pharmanutra presented brilliant 2021 Q1 financial results to […]

24 March 2021

STAR Conference Spring Edition 2021: PharmaNutra meets investors following its first STAR year

The 2021 STAR Conference organised by Borsa Italiana is an opportunity to meet MTA investors following publication of the 2020 […]

05 February 2021

Midcap analysis: PharmaNutra stronger than its peers. Assigned a buy rating with TP at 42 euro.

On 5ᵗʰ February, Midcap produced the “Small Touch” survey highlighting how PharmaNutra is performing more consistently that its peers. As […]

20 January 2021

PharmaNutra participates in the Italian Mid Cap Conference 2021

The third edition of the Italian Mid Cap Conference, organised by Mediobanca officially opened yesterday, seeing the participation of top […]

15 December 2020

PharmaNutra enters the MTA market – STAR segment of Borsa Italiana

This morning saw the floating of shares in PharmaNutra S.p.A. on the MTA market – STAR segment of the Borsa […]

20 July 2020

PharmaNutra: 3 years since being listed on the Market

After three years since being listed on the AIM Italia Market, PharmaNutra takes stock of the situation: from the industrial […]

14 July 2020

PharmaNutra Group: revenue increases +17% in the first half of 2020

PharmaNutra also climbs the annual IQVIA ranking in number of products sold, coming twelfth out of more than 1700 Italian […]

PharmaNutra Spa

Registered office

Via Delle Lenze, 216/b - 56122 Pisa

Phone +39 050 7846500

Fax +39 050 7846524

Electronic billing code

SUBM70N

C.F. / P.Iva / Reg. Impr. 01679440501

Share capital € 1.123.097,70

I.V. | REA 146259

Contacts

Info
info@pharmanutra.it
Commerciale
commerciale@pharmanutra.it
Investor relations
investorrelation@pharmanutra.it
Distribution
internationaldept@pharmanutra.it

Product sites

sideral.it

cetilar.it

ultramag.it

apportal.it

NEWSLETTER

Subscribe to the Pharmanutra newsletter and you will be constantly updated on all our activities.
Read Newsletter Disclosure

Subscribe to the newsletter
Privacy policy Cookie policy General conditions PRIVACY INFORMATION FOR CUSTOMERS

© 2022 2020 PharmaNutra SpA - All rights reserved